Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance

Area of Science:

• Oncology
• Metabolomics
• Biochemistry

Background:

• Lipid metabolism dysfunctions are linked to cutaneous melanoma progression and treatment resistance.
• BRAF/MEK inhibitor resistance in melanoma involves alterations in lipid pathways.

Purpose of the Study:

• To investigate if specific lipid patterns in plasma can characterize melanoma patients.
• To assess the association between lipid profiles and patient response to therapy.

Main Methods:

• Plasma samples from melanoma patients and controls were analyzed for FASN and DHCR24 levels.
• Lipidomic profiling (untargeted and targeted) was performed on plasma samples.
• Patient cohorts were stratified based on clinical response to kinase inhibitors.

Main Results:

• FASN and DHCR24 expression correlated with disease condition and plasma cholesterol/triglycerides.
• Untargeted lipidomics revealed altered fatty acid derivatives and sphingolipids in advanced melanoma.
• Targeted lipidomics showed increased levels of ceramides, sphingomyelins, and fatty acids.
• Specific saturated fatty acids and oleic acid levels differed between patients with long/short-term response to kinase inhibitors.

Conclusions:

• Altered plasma lipid species are associated with a more favorable prognosis in melanoma patients.
• Lipidomic profiling shows potential for stratifying melanoma patients.
• Further research in larger cohorts is warranted to validate these findings.